Astrazeneca Ab

Lena Elisabeth Ripa

Martin Hemmerling

Stephen Connolly

Nafizal Hossain

Grigorios Nikitidis

Igor Shamovsky

Anna Kristoffersson

Johan Rune Michael Lundkvist

Susanne Elisabeth Berglund

Balint Gabos

Kristina Stenvall

Matti Juhani Lepistö

Karl Henrik Edman

Karolina Lawitz

Antonio LLinas

Johan Rune Lundkvist

Matti Juhani Lepisto

Antonio Llinas

Karl Edman

The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).

Chemical compounds

The present invention provides a compound of a formula (I): 

This specification generally relates to 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds (including salts thereof). This specification also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including treatment methods and medicament preparations), and processes for making such a compound.

1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as SGRM modulators

The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD). 

The invention provides compounds of formula (I), wherein Rand Rare as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. 

Hydantoin derivatives for the treatment of obstructive airway diseases

Growing community of inventors

Mölndal, Sweden

Lena Elisabeth Ripa